Biohaven
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Connecticut, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
234 Church St, New Haven, Connecticut, 0...Phone Number
(203) 404-0410Website
www.biohaven.comRevenue
$541.5 MillionStock Symbol
BHVNIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Biohaven
Founded in 2022, Biohaven is a pharmaceutical company developing and commercializing life changing new therapies for people with debilitating diseases.Explore more
Biohaven Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biohaven your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Biohaven, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Biohaven has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Biohaven is spiking on competitors!
Check if Biohaven has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Biohaven had a recent Job posting/layoffs
Earning: See what the market has to say on Biohaven recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Biohaven
Product Launch: Get notified when Biohaven launches new products
Recommended Actions
Find VP level buyers at Biohaven
Find 3 more new buyers
Compare Similar Companies to Biohaven
Compare insights from companies similar to Biohaven, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Biohaven is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Biohaven is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Biohaven.
Biohaven Tech Stack
A closer look at the technologies used by Biohaven
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Partnership, Clinical Operations
Person-Based
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Medical Research, Pharmaceuticals
Biohaven News & Media
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
NEW HAVEN, Conn., July 27, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE: BHVN) and Yale University ("Yale") today announced that a federal jury in the U.S. District Court for the District of Delaware returned a verdict in their favor in the...Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®) Early clinical activity observed: Phase 1 dose-escalation data show early tumor reductions in patients with Fibroblast Growth Factor Receptor (FGFR)3-altered...Biohaven Announces Scientific Leadership Transitions
David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations Warren Volles, General Counsel and Chief Legal Officer, also designated...Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a new class of precision immunology medicines that eliminate the disease-driving antibodies at the root of autoimmune disease. BHV-1300 targets the TSHR-IgG1 autoantibody that drives Graves'...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Biohaven
Sign Up For FreeTo access detailed company insights
Founded in 2022, Biohaven is a pharmaceutical company developing and commercializing life changing new therapies for people with debilitating diseases.... Read More
